Allopurinol - ACE Pharmaceuticals

Drug Profile

Allopurinol - ACE Pharmaceuticals

Alternative Names: ACEPURIN; Allokid®; Allopurinol sodium - ACE Pharmaceuticals

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ace Pharmaceuticals
  • Developer Ace Pharmaceuticals; University Hospital Tubingen
  • Class Antigouts; Purines; Skin disorder therapies
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Asphyxia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asphyxia

Most Recent Events

  • 31 Aug 2017 University Hospital Tuebingen plans the ALBINO phase III trial for Asphyxia (In neonates) in Austria, Belgium, Estonia, Finland, Italy, Netherlands, Norway, Poland, Portugal and Spain(NCT03162653)
  • 02 Aug 2017 Phase-III clinical trials in Asphyxia (In neonates) in Germany, Netherlands, Spain, Finland (IV) (EudraCT2016-000222-19)
  • 25 Jun 2015 Allopurinol - ACE Pharmaceuticals receives Orphan Drug status for Asphyxia in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top